Clinical Trial Update: Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating safety and efficacy of LIPO-202 for reduction of central abdominal bulging due to subcutaneous fat; study completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Abdominal Bulging

Drugs mentioned

• LIPO-202

Snippet

Sponsor: Evofem Inc. | Conditions: Central Abdominal Bulging | Phase 3 | Status: COMPLETED | Results posted: 2019-01-07